Why it matters: For Scancell, the strategic value appears less about Neuphoria’s neuropsychiatry pipeline and more about access to Nasdaq, where specialist biotech investors are deeper and more familiar with late-stage drug development risk.
Zoom in: Neuphoria said it is in discussions about a potential acquisition by Scancell, with Scancell becoming a Nasdaq-listed company after closing. The companies have not disclosed terms, and Neuphoria cautioned that there is no certainty a deal will be agreed or completed.
Backstory: Scancell is trying to build momentum around its cancer immunotherapy pipeline. Its lead programme, iSCIB1+, is being developed for advanced melanoma and is expected to move toward a pivotal Phase III study.
- The company has also reported early clinical promise for Modi-1, its off-the-shelf cancer vaccine targeting citrullinated peptides.
Yes, but: In its latest financial reporting (October 2025), Scancell reported that it only had 8.6 million pounds (€10 million) on hand, making it clear that the company needs to find a source of fresh cash if it wants to finance an expansive Phase III.
- In its statement, the company also said that the reverse merger would be associated with possible equity and debt financing to support the global Phase 3 registrational study for its lead asset.
The other side: Neuphoria is facing difficulties. The US company launched a strategic review after its Phase III AFFIRM-1 study of BNC210 in social anxiety disorder missed its primary and secondary endpoints, prompting the company to halt development in that indication.
- Neuphoria is not just a shell. Its website still lists BNC210 for PTSD, several early-stage CNS programmes and a partnership with MSD covering two drug candidates in Alzheimer’s Disease and cognitive disorders.
- Scancell’s own statement frames the rationale around Nasdaq access and US investor visibility, not about acquiring a portfolio of CNS drugs.
The bottom line: This is a European biotech looking for a US capital-markets upgrade. For Scancell, a reverse merger could offer a shortcut to Nasdaq at a time when it needs funding and visibility for late-stage cancer vaccine development.
Sign up for our newsletter!
